Switch theme
Sign up to access all valuation multiples
Bactiguard Holding AB is a medical device company. It is engaged in the development of infection prevention solutions, which reduce the risk of infections and the use of antibiotics. Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. Its portfolio contains urinary catheters, endotracheal tubes, central venous catheters, Hydrocyn for disinfection and wound care, as well as sutures and other wound care products. Its geographical segments are United States, Sweden, Malaysia, China, Thailand, Bangladesh, New Zeeland, and Other countries.
2005
177
LTM Revenue $26.0M
LTM EBITDA $2.5M
$139M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bactiguard has a last 12-month revenue (LTM) of $26.0M and a last 12-month EBITDA of $2.5M.
In the most recent fiscal year, Bactiguard achieved revenue of $25.1M and an EBITDA of $2.6M.
Bactiguard expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bactiguard valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $26.0M | XXX | $25.1M | XXX | XXX | XXX |
| Gross Profit | $22.3M | XXX | $21.4M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | $2.5M | XXX | $2.6M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBIT | -$2.3M | XXX | -$3.9M | XXX | XXX | XXX |
| EBIT Margin | -9% | XXX | -16% | XXX | XXX | XXX |
| Net Profit | -$2.8M | XXX | -$3.1M | XXX | XXX | XXX |
| Net Margin | -11% | XXX | -12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bactiguard's stock price is SEK 35 (or $4).
Bactiguard has current market cap of SEK 1.2B (or $127M), and EV of SEK 1.4B (or $139M).
See Bactiguard trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $139M | $127M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bactiguard has market cap of $127M and EV of $139M.
Bactiguard's trades at 5.5x EV/Revenue multiple, and 54.1x EV/EBITDA.
Equity research analysts estimate Bactiguard's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bactiguard has a P/E ratio of -45.5x.
See valuation multiples for Bactiguard and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $127M | XXX | $127M | XXX | XXX | XXX |
| EV (current) | $139M | XXX | $139M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 56.7x | XXX | 54.1x | XXX | XXX | XXX |
| EV/EBIT | -59.6x | XXX | -35.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -45.5x | XXX | -41.1x | XXX | XXX | XXX |
| EV/FCF | -450.3x | XXX | 132.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBactiguard's last 12 month revenue growth is 6%
Bactiguard's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Bactiguard's rule of 40 is -32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bactiguard's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bactiguard and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 63% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -32% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 101% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bactiguard acquired XXX companies to date.
Last acquisition by Bactiguard was XXXXXXXX, XXXXX XXXXX XXXXXX . Bactiguard acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bactiguard founded? | Bactiguard was founded in 2005. |
| Where is Bactiguard headquartered? | Bactiguard is headquartered in Sweden. |
| How many employees does Bactiguard have? | As of today, Bactiguard has 177 employees. |
| Who is the CEO of Bactiguard? | Bactiguard's CEO is Mr. Thomas von Koch. |
| Is Bactiguard publicy listed? | Yes, Bactiguard is a public company listed on STO. |
| What is the stock symbol of Bactiguard? | Bactiguard trades under BACTI B ticker. |
| When did Bactiguard go public? | Bactiguard went public in 2014. |
| Who are competitors of Bactiguard? | Similar companies to Bactiguard include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bactiguard? | Bactiguard's current market cap is $127M |
| What is the current revenue of Bactiguard? | Bactiguard's last 12 months revenue is $26.0M. |
| What is the current revenue growth of Bactiguard? | Bactiguard revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Bactiguard? | Current revenue multiple of Bactiguard is 5.4x. |
| Is Bactiguard profitable? | Yes, Bactiguard is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bactiguard? | Bactiguard's last 12 months EBITDA is $2.5M. |
| What is Bactiguard's EBITDA margin? | Bactiguard's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Bactiguard? | Current EBITDA multiple of Bactiguard is 56.7x. |
| What is the current FCF of Bactiguard? | Bactiguard's last 12 months FCF is -$0.3M. |
| What is Bactiguard's FCF margin? | Bactiguard's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of Bactiguard? | Current FCF multiple of Bactiguard is -450.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
